Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM 2802)
Evaristo Maiello, G. Di Maggio, Stefano Cordio, Saverio Cinieri, Francesco Giuliani, Salvatore Pisconti, Antonio Rinaldi, Antonio Febbraro, Tiziana Pia Latiano, Michele Aieta, Antônio Rossi, Daniele Rizzi, Massimo Di Maïo, Giuseppe Colucci, Roberto Bordonaro
Topics & Concepts
BevacizumabMedicineFOLFOXOxaliplatinFolinic acidHazard ratioClinical endpointInternal medicineCapecitabineColorectal cancerOncologyRandomized controlled trialProgression-free survivalNeutropeniaSurgeryConfidence intervalChemotherapyCancerColorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsCancer Treatment and Pharmacology